Literature DB >> 1541671

Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha 1-proteinase inhibitor.

J I Weitz1, E K Silverman, B Thong, E J Campbell.   

Abstract

There is indirect evidence that unopposed human neutrophil elastase (HNE) is responsible for emphysema in patients with alpha 1-proteinase inhibitor (Pi) deficiency. To directly explore this possibility, we developed an assay for fibrinopeptide A alpha 1-21 and its degradation products and used it to measure HNE activity in 128 subjects of known Pi phenotype. The mean elastase-specific fibrinopeptide (ESF) level in 49 deficient PiZ individuals is significantly higher than that in 56 PiMZ heterozygotes (4.5 and 1.5 nM, respectively; P less than 0.01), while the mean ESF value in heterozygotes is significantly elevated over that in 23 normal PiM subjects (1.5 and 0.6 nM, respectively; P less than 0.01), consistent with increased HNE activity in those deficient in the major regulator of the enzyme. These results are not due to differences in smoking history because after correction for pack-years of smoking, ESF values in PiZ subjects are fourfold higher than those in PiMZ individuals (P = 0.005), while the ESF levels in heterozygotes are threefold higher than those in PiM subjects (P = 0.02). In addition, this analysis suggests that cigarette smoking and alpha 1-proteinase inhibitor deficiency have additive effects on ESF levels thereby explaining why PiZ and some PiMZ individuals are at especially high risk for the development of lung disease if they smoke. Finally, the observation that ESF levels in nonsmoking PiZ subjects are inversely related to the percent of predicted forced expiratory volume in 1 s (FEV 1%) provides direct support for the concept that unregulated HNE activity causes alveolar septal destruction in patients with alpha 1-proteinase inhibitor deficiency.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541671      PMCID: PMC442920          DOI: 10.1172/JCI115654

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Alpha 1-antitrypsin Pi types in COPD patients.

Authors:  E D Janus
Journal:  Chest       Date:  1988-08       Impact factor: 9.410

2.  Increased neutrophil elastase activity in cigarette smokers.

Authors:  J I Weitz; K A Crowley; S L Landman; B I Lipman; J Yu
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

3.  Epidemiology Standardization Project (American Thoracic Society).

Authors:  B G Ferris
Journal:  Am Rev Respir Dis       Date:  1978-12

4.  A family study of the variability of pulmonary function in alpha 1-antitrypsin deficiency. Quantitative phenotypes.

Authors:  E K Silverman; M A Province; D C Rao; J A Pierce; E J Campbell
Journal:  Am Rev Respir Dis       Date:  1990-11

5.  Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates.

Authors:  E K Silverman; J A Pierce; M A Province; D C Rao; E J Campbell
Journal:  Ann Intern Med       Date:  1989-12-15       Impact factor: 25.391

6.  Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.

Authors:  J I Weitz; M K Cruickshank; B Thong; B Leslie; M N Levine; J Ginsberg; T Eckhardt
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

7.  Neutrophil-mediated solubilization of the subendothelial matrix: oxidative and nonoxidative mechanisms of proteolysis used by normal and chronic granulomatous disease phagocytes.

Authors:  S J Weiss; J T Curnutte; S Regiani
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

8.  Development of an assay for in vivo human neutrophil elastase activity. Increased elastase activity in patients with alpha 1-proteinase inhibitor deficiency.

Authors:  J I Weitz; S L Landman; K A Crowley; S Birken; F J Morgan
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

9.  Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity.

Authors:  E J Campbell; E K Silverman; M A Campbell
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

10.  Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen.

Authors:  S D Wright; J I Weitz; A J Huang; S M Levin; S C Silverstein; J D Loike
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

View more
  6 in total

1.  Fibrinogenolysis by a neutrophil membrane protease generates an A alpha 1-21 fragment.

Authors:  S L Kelly; S A Adams; S C Robson; R E Kirsch; E G Shephard
Journal:  Biochem J       Date:  1994-03-15       Impact factor: 3.857

2.  Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency.

Authors:  E J Campbell; M A Campbell; S S Boukedes; C A Owen
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

3.  Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation.

Authors:  K Le-Barillec; M Si-Tahar; V Balloy; M Chignard
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

4.  Variants of alpha 1-proteinase inhibitor in black and white South African patients with focal glomerulosclerosis and minimal change nephrotic syndrome.

Authors:  A C Halkas; M C Gaillard; P D Thomson; S L Green; H Ludewick; U Kala
Journal:  J Med Genet       Date:  1998-01       Impact factor: 6.318

Review 5.  New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease.

Authors:  T D Tetley
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

6.  Orphan drug development in alpha-1 antitypsin deficiency.

Authors:  Franziska C Trudzinski; Maria Ada Presotto; Emanuel Buck; Felix J F Herth; Markus Ries
Journal:  Sci Rep       Date:  2022-09-15       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.